Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: A double-blind placebo-controlled trial

British Journal of Haematology

Volumn 101, Issue 2, 1998, Pages 280-286

  Brincker, Hans ^a   Westin, Jan ^b   Abildgaard, Niels ^c   Gimsing, Peter ^d   Turesson, Ingemar ^b   Hedenus, Michael ^e   Ford, John ^f   Kandra, Albert ^f  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d Rigshospitalet   (Denmark)

^e SUNDSVALL HOSPITAL   (Sweden)

^f CIBA GEIGY LTD   (Switzerland)

Author keywords

Bisphosphonates; Multiple myeloma; Pain; Pamidronate; Skeletal morbidity

Indexed keywords

ALPHA INTERFERON; BISPHOSPHONIC ACID DERIVATIVE; MELPHALAN; PAMIDRONIC ACID; PLACEBO; PREDNISOLONE;

ADULT; AGED; ARTICLE; BONE LESION; CANCER PAIN; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DYSPEPSIA; DYSPHAGIA; ENTERIC COATED TABLET; FEMALE; FRACTURE; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADMINISTRATION, ORAL; AGED; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY HEIGHT; BONE DISEASES; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; FRACTURES, BONE; HUMANS; HYPERCALCEMIA; MALE; MELPHALAN; MULTIPLE MYELOMA; PAIN; PREDNISOLONE; TREATMENT FAILURE;

EID: 0031810467     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.00695.x     Document Type: Article

References (25)

1. Belch, A.R., Bergsagel, D.E., Wilson, K., O'Reilly, S., Wilson, J., Sutton, D., Pater, J., Johnston, D. & Zee, B. (1991) Effect of daily etidronate on the osteolysis of multiple myeloma. Journal of Clinical Oncology, 9, 1397-1402.
2. Berenson, J.R. (1997) Bisphosphonates in multiple myeloma. Cancer, Suppl. 80, 1661-1667.
3. Berenson, J.R., Lichtenstein, A., Porter, L., Dimopoulos, M.A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M.J., Blacklock, H.A., Bell, R., Simeone, J., Reitsma, D.J., Heffernan, M., Seaman, J. & Knight, R.D. (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. New England Journal of Medicine, 334, 488-493.
4. Body, J.J., Borkowski, A., Cleeren, A. & Bijvoet, O.M. (1986) Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate. Journal of Clinical Oncology, 4, 1177-1183.
5. Ciba-Geigy Clinical Trial Report PHC 18/1993 (1993) CGP 23339 A. Urinary excretion of pamidronate disodium in patients after a single peroral dose of 300 mg pamidronate disodium (enteric-coated pellet capsules) taken either fasting, before or during breakfast. Ciba-Geigy Ltd, Basle, Switzerland, July 1993.
6. Ciba-Geigy Clinical Trial Report DP/B13 (1995) CGP 23339 A. Comparative multi-centre phase I-II trial in patients with breast cancer and bone metastases. Ciba-Geigy Ltd, Basle, Switzerland, May 1995.
7. Coleman, R.E., Woll, P.J., Miles, M., Schrivener, W. & Rubens, R.D. (1988) Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). British Journal of Cancer, 58, 621-625.
8. Daley-Yates, P.T., Dodwell, D.J., Pongchaidecha, M., Coleman, R.E. & Howell, A. (1991) The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases. Calcified Tissue International 49, 433-435.
9. Elomaa, I., Blomquist, C., Gröhn, P., Porkka, L., Kairento, A.L., Selander, K., Lamherg-Allardt, C. & Holmström, T. (1983) Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet, i, 146-149.
10. Heim, M.E., Clemens, M.R., Queisser, W., Pecherstorfer, M., Boewer, C., Herold, M., Franke, A., Herrmann, Z., Loose, R. & Edler, L. (1995) Prospective randomized trial of dichloromethylene bisphoshonate (clodronate) in patients with multiple myeloma requiring treatment: a multicenter study. Onkologie, 18, 439-448.
11. Hyldstrup, L., Flesch, G. & Hauffe, S.A. (1993) Pharmacokinetic evaluation of pamidronate after oral administration: a study on dose proportionality, absolute bioavailability, and effect of repeated administration. Calcified Tissue International, 53, 297-300.
12. Kanis, J.A., McCloskey, E.V., Drayson, M., Chapman, C. & Dunn, J. (1996) Effect of clodronate on the natural history of myelomatosis. British Journal of Haematology, 93, (Suppl. 2), Abstract 1136.
13. Kyle, R.E. (1975) Multiple myeloma: review of 869 cases. Mayo Clinic Proceedings, 50, 29-40.
14. Lathinen, R., Laakso, M., Palva, I., Virkkunen, P. & Elomaa, I. (1992) Randomized placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet, ii, 1049-1052.
15. Lin, J.H. (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone, 18, 75-85.
16. Morton, A.R., Cantrill, J.A., Pillai, G.V., McMahon, A., Anderson, D.C. & Howell, A. (1988) Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. British Medical Journal, 297, 772-773.
17. Mundy, G.R. (1990) Calcium Homeostasis: Hypercalcemia and Hypocalcemia, pp. 69-115. Martin Dunitz, London.
18. Nussbaum, S.R., Younger, J., Vandepol, C.J., Gagel, R.F., Zubler, M.A., Chapman, R., Henderson, I.C. & Mallette, L.E. (1993) Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30, 60, and 90 mg dosages. American Journal of Medicine, 95, 297-304.
19. Paterson, A.H.G., Powles, T.J., Kanis, J.A., McCloskey, E., Hanson, J. & Ashley, S. (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. Journal of Clinical Oncology, 11, 59-65.
20. Ralston, S.H., Patel, U., Frazer, W.D., Gallagher, S.J., Dryburgh, F.J., Cowan, R.A. & Boyle, I.T. (1989) Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia. Lancet, ii, 1180-1182.
21. Rose, C., Ford, J., Becher, R., Possinger, K., Coleman, R., Rubens, R.D., van Oosterom, A.T. & Tubiana, M. (1992) Pamidronate disodium (Aredia), dose effect and tolerability evaluation in breast cancer patients with bone metastases. Annals of Oncology 3, (Suppl. 5), 85.
22. Shinoda, H., Adamek G., Felix, R., Fleicsh, H., Schenk, R. & Hagan, P. (1983) Structure-active relationships of various bisphosphonates. Calcified Tissue International, 35, 87-99.
23. The Nordic Myeloma Study Group (1996) Interferon-alfa-2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma: a randomized controlled trial. Annals of Internal Medicine, 124, 212-222.
24. van Holten-Verzantvoort, A.T., Bijvoet, O.L.M., Hermans, J., Harinck, H.I.J., Elte, J.W.F., Beex, L.V.A.M., Cleton, F.J., Kroon, H.M., Vermey, P., Neijt, J.P. & Blijham, G. (1987) Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet, ii, 983-985.
25. van Holten-Verzantvoort, A.T., Kroon, H.M., Bijvoet, O.L., Cleton, F.J., Beex, L.V., Blijham G, Hermans, J., Neijt, J.P., Papapoulos, S.E. & Sleebom, H.P. (1993) Palliative pamidronate treatment in patients with bone metastases from breast cancer. Journal of Clinical Oncology, 11, 491-498.